1 Recommendations

1.1 Abiraterone in combination with prednisone or prednisolone is recommended, within its marketing authorisation, as an option for treating metastatic hormone-relapsed prostate cancer:

  • in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated

  • only when the company provides abiraterone in accordance with the commercial access arrangement as agreed with NHS England.

  • National Institute for Health and Care Excellence (NICE)